Understanding Financial Toxicity Among Patients With RCC
Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.
Cristiane D. Bergerot, PhD, of the CETTRO Cancer Research Hospital, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.
Transcription:
0:08 | Patients with renal cell carcinoma experience heightened anxiety about increasing financial toxicity related to COVID-19. They're always also concerned that their money in savings or even retirement assets would not cover the cost of their treatments, or that they will lose their job. It also was interesting that a great proportion of patients do not feel like they are in control of their financial situation.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
